

Material Information (6446 PEC)					
SEQ_NO	2	Date of announcement	2025/05/19	Time of announcement	20:24:18
Subject	The Board Approved to Set Aside the Partial Final Award on the ICC Arbitration Against AOP, and to Request Suspension of the Second Phase of Proceedings				
Date of events	2025/05/19	To which item it meets	paragraph 2		
Statement	<p>1.Parties to the legal matter: Claimant: PharmaEssentia Corporation Respondent: AOP Orphan Pharmaceuticals GmbH (hereinafter referred as AOP)</p> <p>2.Name of the court or punishing agency of the legal matter: (1)Higher Regional Court of Frankfurt am Main, Germany (2)International Chamber of Commerce (ICC) International Court of Arbitration</p> <p>3.Reference/Case number of relevant documents of the legal matter: ICC Case No. 25808/PTA/XZG</p> <p>4.Date of occurrence of the event:2025/05/19</p> <p>5.Details of occurrence (including the matter under dispute): On February 17, 2025, the Company received the Partial Final Award of arbitration from the International Chamber of Commerce (ICC). The Board of Directors approved to file a petition with the Higher Regional Court of Frankfurt am Main, Germany, to set aside parts of the Partial Final Award and to request the arbitral tribunal to suspend the second phase of the arbitration proceedings.</p> <p>6.Handling procedure: I. Following a comprehensive review by the Company’s legal counsel, the Partial Final Award received on February 17, 2025, was found to contain serious procedural defects, including violations of the Company’s right to be heard and the principle of equal treatment. According to established international arbitration practices and Section 1059 of the German Code of Civil Procedure, these defects allow a party to seek annulment within the statutory time limit. With the Board’s approval, the Company will file a petition with the Higher Regional Court of Frankfurt am Main, Germany, to set aside the affected parts of the Partial Final Award. The scope of annulment primarily includes the following: (1)The arbitral tribunal’s dismissal of the Company’s claim for damages resulting from AOP’s delay in applying for U.S. marketing authorization due to lack of causation; and (2)The tribunal’s finding that the Company was liable for a 9.5-month delay in AOP’s European marketing authorization; and (3)The tribunal’s order requiring the Company to bear EUR 1,353,976.63 in prior arbitration costs and to pay AOP EUR 209,036.48 for past clinical supplies. II. Following the filing of the annulment petition, the Company will also promptly request the original arbitral tribunal to suspend the second phase of the arbitration proceedings.</p> <p>7.Impact on the Company’s finance and business and projected amount: Currently, there is no impact on the Company’s finances and business.</p> <p>8.Countermeasures and improvement status: With the Board’s approval, the Company will file a petition with the Higher Regional Court of Frankfurt am Main, Germany, to set aside parts of the Partial Final Award and to request the arbitral tribunal to suspend the second phase of the arbitration proceedings.</p> <p>9.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 2 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): None</p>				